| Abstract |
[Abstract] Objective To explore the effect and mechanism of butylphthalide in adjuvant treatment of Alzheimers disease. Methods Eighty-eight patients with Alzheimers disease in our hospital from January 2018 to August 2019 were the subjects of this study. They were randomly divided into two groups by the number table method. The control group was given conventional treatment, and the observation group was treated with butylphthalide on this basis. Pathological behavior score scale (BEHA VE-AD), living ability scale (ADL), simple mental status checklist (MMSE) and other scales were compared between the two groups before and after treatment. Serum amyloid β (Aβ) level, detection of serum Glutathione peroxidase (GSH-Px), malondialdehyde (MDA), superoxide dismutase (SOD) and other oxidative stress indicators were detected. Endothelin (ET-1), vascular endothelial growth factor (VEGF) And other indicators of vascular endothelial function were detected. Results After treatment, the ADL score and MMSE score of the two groups were significantly increased, and the serum Aβ level and BEHA VE-AD score were significantly reduced. After treatment, the observation group was better than the control group (P<0.05). After treatment, the serum GSH-Px and SOD levels in the two groups increased, while the MDA level decreased. After treatment, the observation group was better than the control group (P<0.05). After treatment, the serum ET-1 levels of the two groups were significantly reduced, and the VEGF levels were significantly increased. After treatment, the observation group was better than the control group (P<0.05). Conclusion Butylphthalide adjuvant treatment of Alzheimers disease can effectively improve their cognition and life ability, which may be related to promoting the reduction of serum Aβ level, reducing oxidative stress, and improving vascular endothelial function.
|